Kairos Pharma, LTD. SEC filings KAPA

Kairos Pharma, LTD. has 125 filings in SEC EDGAR's recent list, going back to Mar 29, 2023. Its latest annual report, Form ARS, was filed on May 22, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (other events). The company's fiscal year ends on December 31.

Kairos Pharma, LTD. SEC filings
Form Description Filed Period
424B3 Prospectus Apr 1, 2026 —
424B3 Prospectus Apr 1, 2026 —
S-3 Shelf registration Jan 13, 2026 —
424B3 Prospectus Aug 19, 2025 —
424B3 Prospectus Apr 25, 2025 —
S-1 Registration statement Apr 22, 2025 —
424B3 Prospectus Feb 5, 2025 —
S-1 Registration statement Jan 29, 2025 —
S-8 Employee stock plan registration Sep 27, 2024 —
424B4 Prospectus Sep 17, 2024 —
S-1/A Amended registration statement Aug 16, 2024 —
S-1/A Amended registration statement Jun 4, 2024 —
S-1/A Amended registration statement May 24, 2024 —
S-1/A Amended registration statement May 20, 2024 —
S-1/A Amended registration statement May 13, 2024 —
S-1/A Amended registration statement May 1, 2024 —
S-1/A Amended registration statement Feb 14, 2024 —
S-1/A Amended registration statement Dec 7, 2023 —
S-1 Registration statement Sep 29, 2023 —

Showing 19 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
KAPA (NYSE)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Los Angeles, CA
SEC filer status
, Emerging growth company
SEC CIK
1962011

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.